



PATENT PC9674BJTJ

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

FILED: January 26, 2001

FOR: Solid Pharmaceutical Dispersions  
With Enhanced Bioavailability

: Examiner: B. Fubara

: Art Unit: 1615

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as First Class Mail in an  
envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231 on

Assistant Commissioner For Patents  
Washington, D.C. 20231this 16<sup>th</sup> day of December 20 00

Sir:

AMENDMENT TRANSMITTAL

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

## CLAIMS AS AMENDED

(1)	(2) Claims Remaining After Amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	Additional Fee
Total Claims	81*	minus	38**	= 43	X \$18.00	774.00
Independent Claims	8*	minus	5***	= 3	X \$84.00	249.00
<input type="checkbox"/> Multiple Dependent Claim(s) fee						\$280.00

\* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.

\*\* If the "Highest No. Previously Paid for" is less than 20, write "20" in this space.

\*\*\* If the "Highest No. Previously Paid for" is less than 3, write "3" in this space.

☐ A Petition for Extension of Time for responding within one (1) month(s) of the response date is also enclosed. Authorization to charge the fee transfer is made separately therein.

☐ No additional fee is required.

☒ Please charge Deposit Account No. 16-1445 in the amount of \$1,023.00. Two copies of this paper are enclosed.

TECH CENTER 1600/2900

JAN 06 2003

RECEIVED

AMENDMENT

☒ The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date: DEC. 16, 2002

James T. Jones  
James T. Jones  
Attorney for Applicant(s)  
Reg. No. 30,561

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 441-4903

C



PATENT PC9674B3J

TECH CENTER 1600/2900

JAN 06 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

FILED: January 26, 2001

FOR: Solid Pharmaceutical Dispersions  
With Enhanced Bioavailability

: Examiner: B. Fubara

: Art Unit: 1615

I hereby certify that this correspondence

is being deposited with the United States

Postal Service as First Class Mail in an

envelope addressed to: Assistant Commissioner

for Patents, Washington, D.C. 20231 on

Assistant Commissioner For Patents  
Washington, D.C. 20231

this 16<sup>th</sup> day of December 20 02

Response Under Rule 111

Sir:

This is in response to the FINAL Office Action dated June 18, 2002, the term for response having been extended three (3) months by including the appropriate fee and petition herewith.

In response to the Office Action, entry of the following changes in the application is respectfully requested:

In the claims:

1. (Twice Amended) A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug having a dose to aqueous solubility ratio greater than 100 mL and hydroxypropylmethylcellulose acetate succinate (HPMCAS), said dispersion providing a maximum concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a control composition comprising an equivalent quantity of undispersed drug.

Cancel claim 2.

Cancel claim 3.

2. (Twice Amended) A composition of matter comprising a spray-dried solid dispersion, which dispersion comprises a sparingly water-soluble drug having a dose to aqueous solubility ratio greater than 100 mL and HPMCAS, said dispersion exhibiting a maximum supersaturated concentration in MFD solution which is higher by a factor of at least 1.5 relative to the equilibrium concentration exhibited by a control composition comprising an equivalent quantity of undispersed drug.

09770562

01/02/2003 JAD001

774.00 CH  
252.00 CH

03 FC:1202  
04 FC:1201